Jubilant Radiopharma will invest $25 million into molecular imaging developer Sofie Biosciences under a new partnership agreement.
Jubilant will have a 25% equity holding in Sofie, with the investment helping Sofie expand production capacity, advance theranostics, and support new PET diagnostic manufacturing and distribution within the U.S. Funds will be used to speed up the readiness timelines of Sofie's theranostics manufacturing facility in Totowa, NJ, and to further develop its fibroblast activation protein inhibitor (FAPI) program.
FAPI is being developed as a theranostic agent to improve the detection and treatment of a wide variety of oncology diseases, according to the company.
